WO1998010078A3 - Cloning of full-length human pex cdna - Google Patents

Cloning of full-length human pex cdna Download PDF

Info

Publication number
WO1998010078A3
WO1998010078A3 PCT/CA1997/000617 CA9700617W WO9810078A3 WO 1998010078 A3 WO1998010078 A3 WO 1998010078A3 CA 9700617 W CA9700617 W CA 9700617W WO 9810078 A3 WO9810078 A3 WO 9810078A3
Authority
WO
WIPO (PCT)
Prior art keywords
pex
renal failure
chronic renal
hyperphosphatemia
cloning
Prior art date
Application number
PCT/CA1997/000617
Other languages
French (fr)
Other versions
WO1998010078A2 (en
Inventor
Andrew C Karaplis
David Goltzman
Janet E Henderson
Mark L Lipman
Dibyendu Panda
Yingnian Shen
Original Assignee
Andrew C Karaplis
David Goltzman
Janet E Henderson
Mark L Lipman
Dibyendu Panda
Yingnian Shen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrew C Karaplis, David Goltzman, Janet E Henderson, Mark L Lipman, Dibyendu Panda, Yingnian Shen filed Critical Andrew C Karaplis
Priority to AU41073/97A priority Critical patent/AU4107397A/en
Priority to CA002264955A priority patent/CA2264955A1/en
Publication of WO1998010078A2 publication Critical patent/WO1998010078A2/en
Publication of WO1998010078A3 publication Critical patent/WO1998010078A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Abstract

The present invention relates to the cloning of full-length human PEX cDNA isolated from tumors causing oncogenous hypophosphatemia osteomalacia, uses of PEX active site for the design of drugs to inhibit protein activity in cases of hyperphosphatemia or chronic renal failure, uses of the PEX active site as a target for the treatment of hyperphosphatemia or chronic renal failure and uses in the diagnosis of hyperphosphatemia or chronic renal failure, use of PEX for the design of drugs to inhibit protein activity in cases of hyperphosphatemia or chronic renal failure, use of PEX as a target for the treatment of hyperphosphatemia, chronic renal failure, hypophosphatemia or idiopathic hypercalcuria, and use of PEX in the diagnosis of hyperphosphatemic states, chronic renal failure, hypophosphatemic states or idiopathic hypercalcuria.
PCT/CA1997/000617 1996-09-05 1997-09-04 CLONING OF FULL-LENGTH HUMAN PEX cDNA WO1998010078A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU41073/97A AU4107397A (en) 1996-09-05 1997-09-04 Cloning of full-length human pex cdna
CA002264955A CA2264955A1 (en) 1996-09-05 1997-09-04 Cloning of full-length human pex cdna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2545496P 1996-09-05 1996-09-05
US60/025,454 1996-09-05

Publications (2)

Publication Number Publication Date
WO1998010078A2 WO1998010078A2 (en) 1998-03-12
WO1998010078A3 true WO1998010078A3 (en) 1998-07-09

Family

ID=21826161

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000617 WO1998010078A2 (en) 1996-09-05 1997-09-04 CLONING OF FULL-LENGTH HUMAN PEX cDNA

Country Status (3)

Country Link
AU (1) AU4107397A (en)
CA (1) CA2264955A1 (en)
WO (1) WO1998010078A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2245903A1 (en) 1998-09-28 2000-03-28 Mcgill University Use of pex in the treatment of metabolic bone diseases
AU2004222823B2 (en) * 1999-02-24 2006-11-30 Enobia Pharma Inc. Composition, Methods and Reagents for the Synthesis of a Soluble Form of Human PHEX
CA2262056A1 (en) 1999-02-24 2000-08-24 Guy Boileau Composition, methods and reagents for the synthesis of a soluble form of human pex
US20030175808A1 (en) * 2000-06-21 2003-09-18 Tomofumi Kurokawa Novel protein and dna thereof
JP2004506046A (en) * 2000-08-23 2004-02-26 バイオメップ　インコーポレイティド Methods and compositions for promoting bone formation
AU2884102A (en) 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A gene ( PEX ) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium.", NATURE GENETICS, vol. 11, no. 2, October 1995 (1995-10-01), pages 130 - 136, XP002056683 *
DATABASE EMBL 21 January 1997 (1997-01-21), LIPMAN M.L. ET AL.: "Human metalloendopeptidase analog (PEX) mRNA, complete sequence.", XP002056687 *
DU L. ET AL.: "cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone.", GENOMICS, vol. 36, no. 1, 15 August 1996 (1996-08-15), pages 22 - 28, XP002056685 *
NELSON A. E. ET AL.: "The PEX gene: not a simple answer for X-linked hypophosphataemic rickets and oncogenic osteomalacia.", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 132, no. 1-2, 19 September 1997 (1997-09-19), pages 1 - 5, XP002056686 *
ROWE P. S.: "Molecular biology of hypophosphatemics rickets and oncogenic osteomalacia.", HUMAN GENETICS, vol. 94, no. 5, November 1994 (1994-11-01), pages 457 - 467, XP002056684 *

Also Published As

Publication number Publication date
WO1998010078A2 (en) 1998-03-12
AU4107397A (en) 1998-03-26
CA2264955A1 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
BR9915134A (en) Co-therapy and combination therapy for the treatment of cardiovascular disorders in an individual, and composition
WO1999017755A3 (en) Medicaments
NZ510509A (en) Compounds that specifically inhibit factor VIIa activity used to inhibit blood clotting and inflammatory response
MX9504415A (en) Aspartate protease substrate isoesters antiviral ethers.
WO2001036365A3 (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
BR9710362A (en) Pharmaceutical formulation compound uses a compound processes of treatment of a human or animal suffering from a mediated by abnormal activity of protein tyrosine kinase and for the preparation of a compound
FR2777183B1 (en) USE OF AT LEAST ONE HYDROXYSTILBENE IN A COMPOSITION FOR PROMOTING DEQUAMATION OF THE SKIN AND COMPOSITION COMPRISING SAME
CA2406057A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
WO2000053749A3 (en) Vascular adhesion molecules and modulation of their function
EP0922461A4 (en) Remedies for hyperphosphatemia
WO1998010078A3 (en) Cloning of full-length human pex cdna
PT1001792E (en) USE OF SALT COMPOUNDS AND PHYSIOLOGICALLY ACHIEVED VANADIAN COMPLEXES
CA2311128A1 (en) Composition with azelaic acid
WO2001034641A8 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
AU2094200A (en) Cosmetic or medical preparation for topical use
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
WO1999055861A3 (en) Fibroblast growth factor mutein compositions and methods of use therefor
EP0375976A3 (en) Compounds binding to a heparin receptor as inhibitors of t cell-mediated immune reactions
GR1003490B (en) Novel pharmaceutical compositions comprising a salt of paraxetine
AU1791497A (en) At1 receptor antagonist for the stimulation of apoptosis
BR0006088A (en) Protein derivatives c
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
EP1652924A3 (en) Polypeptide, cDNA encoding the same and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2264955

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2264955

Country of ref document: CA

NENP Non-entry into the national phase

Ref document number: 1998512071

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 09260045

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase